23 September 2024: Amneal Pharmaceuticals has announced that it has launched CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pellets.
“We are pleased to launch CREXONT and make it broadly available to healthcare providers and patients. The product’s innovative formulation provides a longer duration of “Good On” time with less frequent dosing compared to immediate release CD/LD. As a leader in the Parkinson’s space, Amneal has a long history of working closely with movement disorder specialists and neurologists. We are excited to build on this foundation with the rollout of a comprehensive education program and extensive services to help healthcare providers and patients access this innovative therapy,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty.
CREXONT is now broadly available at US pharmacies, through prescription.
International Congress of Parkinson’s Disease and Movement Disorders
Amneal will hold the following CREXONT events at this year’s International Congress of Parkinson’s Disease and Movement Disorders being held in Philadelphia, PA on Sept. 27 – Oct. 1, 2024:
- Dr. Robert Hauser, CREXONT principal investigator, will present a launch symposium introducing CREXONT on Friday, Sept. 27, 2024 at 1:30 pm ET entitled: Innovation in “On” time is here: introducing CREXONT® (carbidopa and levodopa) extended-release capsules.
- An abstract will be presented highlighting motor states upon awakening with CREXONT (IPX203):Abstract Title: Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data
Abstract Number: 688
Abstract Category: Parkinson’s Disease: Clinical Trials
Presentation Date and Time: Sunday, September 29, 1:00-3:00 pm EDT
Poster Hall: Exhibit Hall A
For additional information about the International Congress of Parkinson’s Disease and Movement Disorders, please click here.
